Protocol Ledger

NCT04079179 · Phase II · RECRUITING

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Interventional Phase II clinical trial protocol NCT04079179 sponsored by Carl Allen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-19 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04079179
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04079179
Protocol FieldVerified Registry Value
NCT IdentifierNCT04079179
Consolidated Lead SponsorCarl Allen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2021-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI